Pharmigene, Inc.

NT$8.10As of Sun 8 Nov 2026, 12:00 UTC
TPEx:7595Healthcare
Country Taiwan
PE (Fwd) •••
TSR 6Y CAGR (17.51%)
Div yield —
ROE (18.32%)
Diagnostics & Research
Beta (5Y) (0.04)
PE TTM —
TSR TTM (19.00%)
Mkt cap NT$408.8M
ROIC (3.07%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$10
26.40%
(35.78%)
Buy 7|1|6|11|2
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.11
0.12
0.12
0.11
28.88%
27.36%
16.31%
5.78%
RevenueNT$M
41.49
41.85
41.55
40.74
(0.06%)
(3.61%)
(3.96%)
(4.15%)
Peers (US$12.27M)
Cap (US$)
PE
21.39M
102.4x
Capital
TTM
5Y
10Y
Leveragex
0.090
0.426
0.307
EBIT/Intx
1.756
0.732
0.625
Own earn%
(171.15)
2.14
(1.00)
Sh yield%
32.97
31.29
32.10
Owners
Insiders/Inst%
8.68
63.23
Short interest%
5.30
SBC / revenue%
1.51
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
16–24
$1 testx
—
Incr. ROIC%
12